📢Publication alert! Highlights: 1⃣ypN+ #UTUC has worse OS vs pN+ 2⃣ypN0 and pN0 pts have similar OS 3⃣All ypN+ pts experience metastasis within 1 year 4⃣89% of ypN+ vs 39% of pN+ have nodal/regional or distant Mets as initial site of recurrence 🔗bit.ly/45peamO

Growing up with money struggles? The emotional toll compounds over decades. USC Dornsife College of Letters, Arts & Sciences found it leads to anxiety & loneliness nearly 20 years earlier than for those who felt financially secure. 📈 dornsife.usc.edu/news/stories/m…

New from the ROBUUST group in Cancers MDPI Farshad Sheybaee Moghaddam Dr. Hooman Djaladat #UTUC #Immunotherapy 🔗Free link access: mdpi.com/2072-6694/17/1…

A sad day indeed. He leaves behind a lasting legacy that will endure for decades. His impact on urologic oncology is profound—ranging from teaching meticulous surgical technique to advancing science through basic and clinical research. We are all feeling this loss and are deeply

Not enough is being said about the impact this will have on lower income students’ ability to afford away rotations, step prep materials, professional clothing, or even bank more time for studying or sleep by purchasing premade meals. #BigBeautifulBill #MedTwitter #AAMC

Should #radicalcystectomy ever be considered for consolidate therapy post EV/P?dailynews.ascopubs.org/do/personalizi… Petros Grivas Shilpa Gupta Tom Powles Matt Galsky Oncology Brothers Sumanta K. Pal, MD, FASCO Yüksel Ürün niraj Ashish M. Kamat, MD, MBBS IBCG SWOG Cancer Research Network Society of Urologic Oncology Bladder Cancer Advocacy Network

In the era of EV plus pembro, where does radical cystectomy fit into treatment plans for patients with urothelial carcinoma? Sia Daneshmand, M.D. provides a detailed overview for #ASCODailyNews: brnw.ch/21wUqpv

Just published online in Journal of Clinical Oncology : #SunRISe1 Phase IIb results show TAR-200 (novel intravesical drug releasing system) achieves 82.4% CR in BCG-unresponsive high-risk NMIBC—with durable responses (median DOR 25.8 mo) & low toxicity. A game-changer for pts with #NMIBC.

Congratulations Alireza Ghoreifi, MD!!

It is our pleasure to welcome back our newest faculty member, Leilei Xia, MD.  For more on Leilei Xia, please visit: instagram.com/pennsurgery

We investigated whether MRI visibility predicts outcomes after focal therapy for prostate cancer. Our findings suggest that highly visible lesions on MRI are associated with worse oncologic outcomes—even after focal therapy. bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bc…

Watch our Public Programs Coordinator, Krystal, explain the difference between a seal and a sea lion! Join us August 24 for Marine Science Sunday to learn more about the marine mammals that call the Bay home. Tickets are free, so reserve today 🤩👉 bit.ly/3PX8TI5.

New hope for bladder cancer patients goodmorningamerica.com/video/124640406

Outstanding work. Would really love to see this applied to low income students matriculating to medicine next.

Phase II SunRISe-1: TAR-200 (slow drug-releasing system for gemcitabine) achieved CR in 82% of pts with BCG-unresponsive high-risk NMIBC Journal of Clinical Oncology 🩺Sia Daneshmand, M.D. ❕#FDA priority review granted ascopost.com/news/august-20…

In memoriam: Dr. Donald G. Skinner keck.usc.edu/news/in-memori…

Efficacy and Durability of Response in SunRISe-1 with Joe Jacob MD, MCR guoncologynow.com/post/efficacy-…

👇 Check out our new video interview featuring Drs. Daneshmand and Jacob on the use of TAR-200 in #bladdercancer!

🔥Just in BJU International! 🥇The first structured training curriculum for RARNU using international expert consensus Link🔗bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj… Farshad Sheybaee Moghaddam Rashid K. Sayyid Dr. Hooman Djaladat

Eirik Kjøbli performing Robo cystectomy neobladder w en bloc PLND. Data showing better oncologic outcomes compared to template LND! Full circle from Donald Skinner original description. @ St Olav's University Hospital #Trondheim #Norway Torgrim Tandstad @Jürgen E. Gschwend